GCV Symposium
Skip Content

20 April 2017

G1 goes for $115m IPO

The oncology drug developer has raised $92.5m in VC funding, $11.5m of which came from MedImmune Ventures, the CVC unit that now owns a 16.7% stake.

Author: Robert Lavine, News Editor

US-based oncology therapy developer G1 Therapeutics has filed for a $115m initial public offering that will provide an exit for MedImmune, a subsidiary of pharmaceutical firm AstraZeneca.